Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Impact · against what's priced in

Arrowhead Pharmaceuticals receives a positive catalyst via Health Canada approval for REDEMPLO in the treatment of FCS. This authorization opens a new commercial market and validates the drug's regulatory path, providing a modest lift to growth expectations.

ARWR+0.40: No priced-in read yet

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

What matters in this story

How each ticker is affected

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

What matters in this story

How each ticker is affected

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Track these names every morning.

Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

What matters in this story

How each ticker is affected

Next reads from the same story arc

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

What matters in this story

How each ticker is affected

Next reads from the same story arc

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Track these names every morning.

Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript